Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.

Launched by KING FAISAL HOSPITAL RWANDA · Mar 23, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to eliminate malaria in Rwanda by targeting people who have the malaria parasite but do not show symptoms, known as asymptomatic reservoirs. Researchers believe that using locally available Artemisia tea could help treat these hidden infections. This is important because these asymptomatic individuals can still spread the malaria parasite to mosquitoes, which can then infect others. The results of this study will provide valuable information for health decision-makers and could have a significant positive impact on the community and economy in Rwanda.

To participate in this trial, you need to be between 18 and 65 years old, in good health, and confirmed to have an asymptomatic malaria infection. You should also have lived in Rwanda for at least a month and not be taking any other malaria medications. Participants will not only contribute to important research but also help improve future malaria control strategies. It's also essential to know that certain medical conditions and pregnancy may prevent someone from joining the study. The trial is currently not recruiting participants yet, but it aims to gather information that could change how malaria is treated and controlled in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed as asymptomatic reservoir of Plasmodium in the community or after completing standard malaria treatment.
• • Leave for at least one month in Rwanda for non-national
• • Be between 18 and 65 years of age, and in good general health.
• • Not taking any other malaria drug for prevention or treatment.
• • Children 5 years and above will be recruited as index cases for household cluster survey.
• Exclusion Criteria:
• • Have known hypersensitivity to any ingredients of the test treatment.
• • Have participated in any other malaria drug trial or device less than 14 days before.
• • History or presence of clinically significant medical, psychiatric, or emotional condition that would compromise the safety of the subject or adherence to the interventional requirements.
• • Be pregnant